<div class="subscription-widget-wrap-editor"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading Stock Analysis Compilation! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input class="email-input" name="email" tabindex="-1" type="email" /><input class="button primary" type="submit" value="Subscribe" /><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><div><hr /></div><h3><strong>Upgrade Your Edge on HFBestIdeas.com</strong> 🚀</h3><p>Stop spending hours sourcing and digesting Hedge Fund letters. Let HFBestIdeas do the manual work for you and turn over more rocks in less time. </p><p><strong>Try any premium plan free for 7 days:</strong></p><ul><li><p><strong>The Analyst ($10/mo):</strong> Full newsletter (35+ stock pitches/week).</p></li><li><p><strong>The Associate ($19/mo):</strong> Full access to our pitch database + Quarterly Letter archive.</p></li><li><p><strong>The Rainmaker ($29/mo):</strong> Total access + <strong>Warren AI</strong>, your proprietary research assistant.</p></li></ul><p><em>Note: For Associate & Rainmaker access, please subscribe directly at <a href="https://HFBestIdeas.com">HFBestIdeas.com</a>.</em></p><p class="button-wrapper"><a class="button primary" href="https://www.hfbestideas.com/pricing"><span>Start Your 7-Day Free Trial</span></a></p><p>Now, let’s get into this week’s selection of fund ideas 👇</p><div><hr /></div><h3>Summary :</h3><p>🔹 Abbott Laboratories (ABT US) by The Davenport Funds<br />🔹 Accenture (ACN US) by Harris Associates U.S. Large Value Strategy<br />🔹 Adyen NV (ADYEN NA) by Guinness Global Quality Mid Cap<br />🔹 Alphabet Inc. (GOOGL US) by Baron Opportunity Fund<br />🔹 Amphenol Corporation (APH US) by Baron Fifth Avenue Growth Fund<br />🔹 Arthur J. Gallagher & Co. (AJG US) by Large-Cap Growth<br />🔹 AstraZeneca PLC (AZN LN) by Bell Global Equities Fund<br />🔹 Bajaj Finance Limited (BAF IN) by Baron Global Opportunity Fund<br />🔹 BillionToOne, Inc. (BLLN US) by Baron Health Care Fund<br />🔹 Boston Scientific (BSX US) by CDT<br />🔹 Broadridge Financial Solutions, Inc. (BR US) by The Davenport Funds<br />🔹 Cameco Corporation (CCO CN) by Alger International Opportunities Fund<br />🔹 Cameco Corporation (CCJ US) by Alger International Opportunities Fund I<br />🔹 Casella Waste Systems, Inc. (CWST US) by Alger Weatherbie Specialized Growth Fund<br />🔹 Cirsa Enterprises (CIRSA SM) by Palm Harbour Capital<br />🔹 Constellation Software (CSU CN) by Emerald Focused Equity Strategy<br />🔹 CoStar Group, Inc. (CSGP US) by Baron First Principles ETF<br />🔹 DCC plc (DCC LN) by EQUAM Global Value Fund<br />🔹 Energias de Portugal (EDP PL) by Cambiar International Equity<br />🔹 Forgent Power Solutions, Inc. (FPS US) by Baron Opportunity Fund<br />🔹 Globus Medical (GMED) by Gabelli Funds<br />🔹 Guidewire Software, Inc. (GWRE US) by Baron Small Cap Fund<br />🔹 Hermès International (RMS FP) by Bell Global High Conviction Fund<br />🔹 Hyosung Corporation (298040 KS) by AVI Global Special Situations<br />🔹 Intuit Inc. (INTU US) by Brown Advisory Global Leaders<br />🔹 IQVIA (IQV US) by Broyhill AM<br />🔹 Jungfraubahn Holding AG (JFN SW) by Tactile Fund<br />🔹 Lam Research Corporation (LRCX US) by Baron Opportunity Fund<br />🔹 MAMA (MAMA US) by Long Cast Advisers<br />🔹 Microsoft (MSFT US) by AGT Partners<br />🔹 Mitsubishi Heavy Industries (7011 JP) by Polen International Growth<br />🔹 Nomura Research Institute, Ltd. (4307 JP) by Bell Global Emerging Companies Fund<br />🔹 NVIDIA (NVDA US) by Antipodes Global Value Fund<br />🔹 Olin Corporation (OLN US) by Hotchkis & Wiley Large Cap Fundamental Value<br />🔹 Park Systems Corporation (140860 KS) by Baron International Growth Fund<br />🔹 PDEX (PDEX US) by Long Cast Advisers<br />🔹 Pet Valu Holdings (PET CN) by Bristol Gate Canadian Equity<br />🔹 Pro Medicus (PME AU) by Vision Capital Fund<br />🔹 RaySearch Laboratories (RAY B SS) by Goodhart European Fund<br />🔹 Ryanair (RYA ID) by Harding Loevner Global Equity<br />🔹 Saab (SAAB B SS) by Polen International Growth<br />🔹 Sandoz Group Ltd. (SDZ SW) by Hardman Johnston International Equity Developed Markets<br />🔹 Siemens Energy (ENR GY) by Polen Global Growth<br />🔹 Taiwan Semiconductor Manufacturing Co., Ltd. (TSM US) by Hardman Johnston Global Equity<br />🔹 The Baldwin Group Inc (BWIN US) by Artisan U.S. Small-Cap Growth Strategy<br />🔹 Tidewater (TDW US) by Black Bear Value Fund<br />🔹 Valvoline, Inc. (VVV US) by Brown Advisory U.S. Small-Cap Blend UCITS Fund<br />🔹 Verisure (VSURE SS) by EQUAM Global Value Fund<br />🔹 Walt Disney (DIS US) by Antipodes Global Value Fund<br />🔹 WEG (WEG3 BZ) by Harding Loevner Emerging Markets Equity</p><div><hr /></div><h3>Abbott Laboratories ($ABT US)</h3><p><strong>Fund:</strong> The Davenport Funds</p><p><strong>Thesis:</strong> Abbott Laboratories is a diversified healthcare company with an expanded diagnostics market, accelerating growth guidance, and insider buying.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=00oXbNl3PjuF">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>Abbott is a diversified healthcare company, serving end markets across medical devices, diagnostics, established pharmaceuticals, and nutrition. Its recent acquisition of Exact Sciences expands its diagnostics addressable market, and should accelerate growth. Abbott’s stock had declined after the company reported a lackluster December quarter result, with the Nutrition segment’s -9% organic revenue growth being the key culprit. Meanwhile, total company organic growth was +3.8% in the quarter and +5.5% for the year, with 2026 guided to accelerate toward +6.5 to +7.5% on the back of new product launches. The CEO purchased $2M+, followed by a $1M+ purchase from a long-tenured Board member.</p><p><a href="https://www.hfbestideas.com/?q=ABT+US&page=1">Access our full research database on Abbott Laboratories</a></p><div><hr /></div><h3>Accenture ($ACN US)</h3><p><strong>Fund:</strong> Harris Associates U.S. Large Value Strategy</p><p><strong>Thesis:</strong> Accenture combines unmatched scale, embedded enterprise relationships, and cloud-transition tailwinds with a discounted valuation.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=C4idSo4dtunN">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>• Accenture is a global leader in consulting and outsourced IT services. The company benefits from unmatched scale, being nearly three times as large as the next three public IT services companies combined. We think it is well-positioned for future growth as it is deeply embedded in large enterprises’ workflows, with its top 300 clients spending over $100 million annually. Furthermore, we believe it is poised to capitalize on the ongoing enterprise cloud transition and the secular growth in enterprise technology spending. Despite these strong fundamentals, the stock is trading at its lowest P/E multiple since 2015 due to what we view as misguided AI disruption fears, creating the opportunity to purchase shares at a sizable discount to our estimate of intrinsic value.</p><p><a href="https://www.hfbestideas.com/?q=ACN+US&page=1">Access our full research database on Accenture</a></p><div><hr /></div><h3>Adyen NV ($ADYEN NA)</h3><p><strong>Fund:</strong> Guinness Global Quality Mid Cap</p><p><strong>Thesis:</strong> Adyen NV is a network-agnostic, end-to-end payments platform with strong merchant-led growth and an attractive entry point after a de-rating.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=N9LMnrGw9Yp7">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>Adyen is a digital-first, end-to-end payments platform connecting merchants directly to card networks — delivering higher authorisation rates, lower false positives, and a unified view of the customer across channels and geographies. It is a smaller-cap alternative to Visa and Mastercard, but sits closer to the merchant and offers genuine software value-add on top of pure processing. Both large-cap peers have faced multiple compression from regulatory pressure on interchange fees, while the broader payments sector has been weighed down by stablecoin fears — the prospect of peer-to-peer digital settlement bypassing card networks entirely. Adyen is better positioned than most to navigate this, having developed infrastructure to accept stablecoin payments and positioning itself as network-agnostic. Over 80% of volume growth comes from existing merchants, with further runway from POS expansion and the secular shift to cashless commerce. The stock de-rated sharply after the recent quarterly earnings narrowly missed expectations, whilst broader weakness in payment businesses (given their software nature) left the valuation at a fraction of historical levels, creating a compelling entry point into a highly cash-generative business.</p><p><a href="https://www.hfbestideas.com/?q=ADYEN+NA&page=1">Access our full research database on Adyen NV</a></p><div><hr /></div><h3>Alphabet Inc. ($GOOGL US)</h3><p><strong>Fund:</strong> Baron Opportunity Fund</p><p><strong>Thesis:</strong> Alphabet is a highly integrated AI and digital advertising franchise with unmatched distribution, proprietary data, and attractive valuation.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=XhyYLY29RL2u">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>During the first quarter, we initiated a position in Alphabet Inc., the parent company of Google and one of the world’s most valuable technology franchises. After missing Alphabet’s strong run in the latter part of 2025, we took a fresh look at the competitive landscape across hyperscalers and frontier AI labs and concluded that Alphabet offers the most compelling combination of assets in AI at an attractive valuation. We believe that combination includes unmatched consumer distribution across Search, YouTube, Chrome, and Android — including seven products with over two billion users each — proprietary Gemini frontier models, custom tensor processing unit chips, owned data center infrastructure, and decades of unrivaled user and advertiser data. This fully integrated and cost-advantaged AI stack is funded by one of the most cash-generative business models in the world. Despite the rise of AI-native competitors, Search and YouTube continue to grow at double-digit rates at enormous scale and have not missed advertising revenue expectations once since the launch of ChatGPT in November 2022. Meanwhile, Google Cloud is accelerating (we are projecting over 60% year-over-year revenue growth for this segment), driven by demand from leading frontier AI labs and a growing base of AI-forward enterprise customers. We are also encouraged by management’s observation that AI features are deepening user engagement rather than disrupting it, with more complex and multimodal queries driving more time on platform. Alphabet is one of a very small number of companies in the world with the distribution, capital, proprietary data, and technical infrastructure to compete and win across multiple layers of the AI ecosystem simultaneously — and at a reasonable valuation, we see a compelling long-term opportunity for shareholders.</p><p><a href="https://www.hfbestideas.com/?q=GOOGL+US&page=1">Access our full research database on Alphabet Inc.</a></p><div><hr /></div><h3>Amphenol Corporation ($APH US)</h3><p><strong>Fund:</strong> Baron Fifth Avenue Growth Fund</p><p><strong>Thesis:</strong> Amphenol is a diversified interconnect leader with a strong culture, AI-driven growth acceleration, and a long runway for compounding.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=4EeYXoNo8VRQ">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>This quarter we initiated a position in Amphenol Corporation, a leading provider of high-technology interconnect, sensor, and antenna solutions to a diverse set of end markets. Amphenol is a highly diversified business operating in seven different end markets – Industrial, Automotive, Mobile Devices, IT Datacom, Communications Networks, Defense, and Commercial Aerospace. The company’s mission-critical products are needed in electrical systems to move data, transmit signals, and enable specific outcomes. As the world electrifies and more systems move from analog to digital, Amphenol’s content opportunity grows. The hallmark of the company is its unique, decentralized “Amphenolian” culture in which over 140 general managers each have autonomy over their individual business units. This leads to a highly agile organization that can quickly respond to market trends (speaking of adaptability to change) with best-in-class products and deliver them on a global scale. This culture has enabled the company to compound growth in revenue and cash flow over many years through both above-market organic growth and a long history of successful M&A. Culture is set from the top, with long-time CEO Adam Norwhitt saying on many occasions that his number one priority is to preserve and scale the unique Amphenolian culture. He has been a great capital allocator over his more than 15 years as the CEO, and we expect that to continue.</p><p>Amphenol historically had a balanced exposure across many end markets, delivering consistent organic growth above an underlying interconnect end market already growing a healthy mid-single-digit rate over time. Recently, however, Amphenol’s exposure to data center infrastructure spending through connectors and cables in AI server racks drove a significant growth acceleration, with its IT Datacom segment now close to 40% of sales having grown from a less than $3 billion annual run rate to a $10 billion run rate as of the most recent quarter over just two years. While usually companies progress from being Big Ideas to Durable compounders, in this case, we are seeing the opposite trend as Amphenol is increasingly becoming a Big Idea thanks to its AI business and the significant AI buildout, which we believe will continue.</p><p>The stock, however, has experienced volatility recently due to a debate around the company’s content in future AI racks moving to optical networking from copper given Amphenol has historically been considered a strong player in copper and less so in optical. We believe shares have been overly penalized on this risk underestimating Amphenol’s ability to innovate and adapt as it has over many years and across many cycles and end markets – creating a solid entry point for long-term investors. The company recently closed its largest acquisition in history in CommScope Connectivity and Cable Solutions for $10.5 billion, an optical specialist, and management consistently talks about how they are always in conversations with key customers about multiple generations of product roadmaps into the future. It is clear why Amphenol was so excited to acquire CommScope, let alone for a very reasonable over 12 times 2025 EBITDA, and we have strong confidence that the team can continue to deliver and have the right products at the right time to serve the market’s needs as they did in the current wave of AI capex.</p><p>While we expect the data center segment to continue to lead growth for the company, the rest of the business is also delivering outstanding growth having finished 2025 with 10% organic growth despite a weak global industrial spend environment, once again reflecting the unique franchises throughout the company. Margins are also at all-time highs and are expected to continue to expand as sales volume grows over time. Through a combination of organic growth both within the IT Datacom segment and throughout its other end market exposures, continued margin expansion, capital allocation towards accretive M&A, and a strong management team grounded in a unique culture, we believe the company has a long runway for growth ahead.</p><p><a href="https://www.hfbestideas.com/?q=APH+US&page=1">Access our full research database on Amphenol Corporation</a></p><div><hr /></div><h3>Arthur J. Gallagher & Co. ($AJG US)</h3><p><strong>Fund:</strong> Large-Cap Growth</p><p><strong>Thesis:</strong> Arthur J. Gallagher is a fee-based insurance broker with scale advantages, favorable industry tailwinds, and low AI disruption risk.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=cg9RpsKlsGdk">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>Arthur J. Gallagher & Co (AJG) is a leading global insurance brokerage and risk management firm with a highly recurring, fee-based revenue model. The company is a market leader in the middle-market segment, where its scale, data advantages, and advisory capabilities differentiate it from smaller competitors. We believe the business is well positioned to benefit from favorable industry dynamics, including increasing complexity of risk, underinsurance, and continued consolidation in a highly fragmented market. In addition, we see limited risk from AI-driven disintermediation, as the advisory nature of the business and focus on more complex accounts remain difficult to replicate.</p><p><a href="https://www.hfbestideas.com/?q=AJG+US&page=1">Access our full research database on Arthur J. Gallagher & Co.</a></p><div><hr /></div><h3>AstraZeneca PLC ($AZN LN)</h3><p><strong>Fund:</strong> Bell Global Equities Fund</p><p><strong>Thesis:</strong> AstraZeneca is a diversified biopharmaceutical compounder with a high-quality pipeline, durable growth, and attractive valuation.</p><p><strong>Source:</strong> <a href="https://drive.google.com/file/d/151yq3z2Mm1gjhHx367c7vi30aUdDDYHQ/view?usp=drivesdk">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>Among the portfolio changes in April, we established a position in global biopharmaceutical company AstraZeneca, where we are attracted to the company’s diversified and high-quality pipeline, underpinning a strong outlook for sustainable earnings growth over the medium term. The company has built a broad portfolio across oncology, rare diseases, and biopharmaceuticals, reducing reliance on any single asset and providing meaningful pipeline optionality over the medium term. Management has demonstrated consistent execution in E&D and commercialisation, translating innovation into durable growth. Importantly, AstraZeneca has a well-diversified revenue base and manageable patent exposure, supporting visibility on earnings and cash flow. Recent results were solid, reinforcing confidence in the underlying trajectory. The stock has, however, pulled back following concerns around camizestrant, a breast cancer pipeline asset, after a negative FDA advisory committee vote. While this reduces the probability of approval in that indication, we do not view it as material to the broader investment case given the depth and diversity of the pipeline. Overall, we see AstraZeneca as a high-quality compounder, with recent weakness providing an opportunity to initiate exposure at a more attractive valuation.</p><p><a href="https://www.hfbestideas.com/?q=AZN+LN&page=1">Access our full research database on AstraZeneca PLC</a></p><div><hr /></div><h3>Bajaj Finance Limited ($BAF IN)</h3><p><strong>Fund:</strong> Baron Global Opportunity Fund</p><p><strong>Thesis:</strong> Bajaj Finance is a leading Indian NBFC leveraging proprietary data and AI with strong management and long-term growth prospects despite short-term macro headwinds.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=aC9NcgbJioaz">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>Bajaj Finance illustrates how proprietary data compounds into product advantage in financial services. The company has lending data on over 100 million Indian consumers across 26 product categories. In the last quarter alone, its AI systems listened to 20 million customer calls, converted voice to text, extracted structured data on 520,000 customers, and generated 100,000 new personalized loan offers that the company previously lacked the information to make, producing ₹1,600 crore in disbursals, roughly 10% of quarterly volume. This is a capability that did not exist two quarters earlier. Each call makes the models smarter: better at identifying which customers to target, what products to offer, and when to offer them. Vice Chairman Rajeev Jain commented on the earnings call: “We are not testing AI. We are deploying AI across the board, across the life cycle.”</p><p>Bajaj Finance Limited is a leading non-bank financial company in India. Shares declined 22.3% during the quarter as geopolitical tensions over the past month raised expectations of higher inflation and disrupted India’s easing interest rate environment, which could negatively impact consumption-led credit growth in the short term. We retain conviction in the company due to its best-in-class management team, robust long-term growth outlook, and conservative risk management frameworks. We believe Bajaj is well positioned to benefit from growing demand for consumer financial services in India, including mortgages, personal loans, credit cards, and other related products. We also believe the company will be an AI beneficiary thanks to its robust proprietary data and tech stack, which enables it to both run the business more efficiently and drive incremental loan growth.</p><p><a href="https://www.hfbestideas.com/?q=BAF+IN&page=1">Access our full research database on Bajaj Finance Limited</a></p><div><hr /></div><h3>BillionToOne, Inc. ($BLLN US)</h3><p><strong>Fund:</strong> Baron Health Care Fund</p><p><strong>Thesis:</strong> BillionToOne is a differentiated diagnostics company with strong prenatal traction, early oncology potential, and attractive margins.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=Avs0HnMX5xfi">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>We added to the Fund’s investment in BillionToOne, Inc., a diagnostics company that is disrupting the market with more accurate prenatal and oncology genetic tests. At the core is the company’s innovative quantitative counting template (QCT) technology, which allows BillionToOne to accurately count the number of mutation copies at a single-gene level. BillionToOne generates the vast majority of its revenue today from UNITY, which is a differentiated prenatal genetic test. Traditional prenatal tests can check for chromosomal abnormalities like Down syndrome but require more invasive testing to test for single gene inherited disorders. UNITY is a single blood draw from the mom that can screen for chromosomal problems and provide an accurate risk assessment for recessive single-gene disorders. BillionToOne has already captured 15% of the $2 billion-plus U.S. prenatal screening market (according to our estimates) in a short period of time, and we expect them to continue to gain share. BillionToOne is also making early headways in oncology, which represents a $50 billion-plus total addressable market, according to our estimates. The same QCT technology powers BillionToOne’s NORTHSTAR SELECT therapy selection test, which can find 51% to 109% more actionable mutations than competitor tests. The test has a much lower lower-limit-of-detection compared to competitors and can detect driver mutations even when the allele copy number is low. BillionToOne also offers NORTHSTAR RESPONSE, which is a new type of test that can detect subtle change in a cancer patient’s tumor burden and can track whether the patient is responding to therapy. We are optimistic that more data about RESPONSE this year will enable broad Medicare reimbursement for the test. BillionToOne’s launch in oncology is still nascent, but we think this product differentiation will help BillionToOne capture share in this large and growing market. Impressively, BillionToOne has accomplished all of this while maintaining financial discipline. The company has 70% gross margins and has already achieved GAAP profitability and positive free cash flow.</p><p><a href="https://www.hfbestideas.com/?q=BLLN+US&page=1">Access our full research database on BillionToOne, Inc.</a></p><div><hr /></div><h3>Boston Scientific ($BSX US)</h3><p><strong>Fund:</strong> CDT</p><p><strong>Thesis:</strong> Boston Scientific is presented as a high-quality company with insider buying, growing sales, and a valuation discount.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=iTe2s30cepTb">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>Increasingly insiders from high caliber companies such as Boston Scientific (BSX), Intuit (INTU), Textron (TXT), Flowserve (FLS) and Cencora (COR) are buying up the shares of the businesses they manage. All of which share something in common. Their stock prices are down -10% to -55%, but year-over-year their sales are up, they trade at well below market multiples and they all maintain an Investment Grade credit profile with the rating agencies. Translation, these are well above average companies trading at a significant discount to the average stock. It is in this part of the market where we add value to our partners. As the chase for AI continues, we will find real value in some of the largest companies in the world that have simply been ignored.</p><p><a href="https://www.hfbestideas.com/?q=BSX+US&page=1">Access our full research database on Boston Scientific</a></p>
<p>
<a href="https://hfbestideas.substack.com/p/50-new-pitches-found-in-hedge-fund">
Read more
</a>
</p>